Garassino, Marina ChiaraCho, Byoung-ChulKim, Joo-HangMazières, JulienVansteenkiste, JohanLena, HervéJaime, Jesus CorralGray, Jhanelle EPowderly, JohnChouaid, ChristosBidoli, PaoloWheatley-Price, PaulPark, KeunchilSoo, Ross APoole, LynneWadsworth, CatherineDennis, Phillip ARizvi, Naiyer A2023-02-092023-02-092020-06-30http://hdl.handle.net/10668/15981In the phase II ATLANTIC study, durvalumab provided durable responses with acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three independent patient cohorts defined by EGFR/ALK status and tumour PD-L1 expression. Preliminary overall survival (OS) data were encouraging. We now report final OS and updated safety data. Patients with advanced NSCLC with disease progression following ≥2 previous systemic regimens received durvalumab 10 mg/kg every 2 weeks. The primary endpoint was objective response rate among patients with increased PD-L1 expression (defined as ≥25 % or ≥90 % of tumour cells [TCs], cohort-dependent). Secondary endpoints included OS and safety. 444 patients received durvalumab: 111 in Cohort 1 (EGFR+/ALK+), 265 in Cohort 2 (EGFR-/ALK-), and 68 in Cohort 3 (EGFR-/ALK-; TC ≥ 90 %). Median (95 % CI) OS was 13.3 months (6.3-24.5) in patients with EGFR+/ALK+ NSCLC with TC ≥ 25 %, 10.9 months (8.6-13.6) in patients with EGFR-/ALK- NSCLC with TC ≥ 25 %, and 13.2 months (5.9-not reached) in patients with EGFR-/ALK- NSCLC with TC ≥ 90 %. Median (95 % CI) OS was slightly shorter in patients with TC  After additional follow-up, final OS data remain encouraging across all cohorts, further supporting the clinical activity of durvalumab in patients with heavily pretreated advanced NSCLC, including those with EGFR+/ALK+ tumours. There were no new safety signals.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/ATLANTICDurvalumabNSCLCOverall survivalSafetyAntibodies, MonoclonalCarcinoma, Non-Small-Cell LungCohort StudiesHumansLung Neoplasmsresearch article32702570open access10.1016/j.lungcan.2020.06.0321872-8332http://www.lungcancerjournal.info/article/S0169500220305067/pdf